PUCCI, FRANCESCO
 Distribuzione geografica
Continente #
NA - Nord America 88
AS - Asia 65
EU - Europa 26
SA - Sud America 23
Continente sconosciuto - Info sul continente non disponibili 3
AF - Africa 2
Totale 207
Nazione #
US - Stati Uniti d'America 87
SG - Singapore 20
BR - Brasile 17
VN - Vietnam 17
CN - Cina 9
HK - Hong Kong 8
IT - Italia 7
SE - Svezia 5
GB - Regno Unito 4
RU - Federazione Russa 4
IN - India 3
AR - Argentina 2
EC - Ecuador 2
FI - Finlandia 2
FR - Francia 2
PK - Pakistan 2
BD - Bangladesh 1
CA - Canada 1
CO - Colombia 1
DE - Germania 1
DK - Danimarca 1
EG - Egitto 1
IQ - Iraq 1
KR - Corea 1
MA - Marocco 1
NP - Nepal 1
SA - Arabia Saudita 1
TR - Turchia 1
VE - Venezuela 1
Totale 204
Città #
Singapore 10
Chandler 9
Fairfield 8
Hong Kong 8
San Jose 7
Ashburn 5
Cambridge 4
Ho Chi Minh City 4
Woodbridge 4
Ann Arbor 3
Beijing 3
Hanoi 3
Houston 3
New York 3
Nyköping 3
Seattle 3
São Paulo 3
Des Moines 2
Helsinki 2
Inglewood 2
Lauterbourg 2
Lawrence 2
London 2
Norwalk 2
Philadelphia 2
Pisa 2
Bologna 1
Buffalo 1
Buford 1
Bắc Giang 1
Cachoeirinha 1
Cairo 1
Campo Grande 1
Candói 1
Caracas 1
Central Islip 1
Chennai 1
Chongqing 1
Copenhagen 1
Cuenca 1
Da Nang 1
Dallas 1
Delhi 1
Dhaka 1
El Empalme 1
Elk Grove 1
Grottaminarda 1
Guarujá 1
Huế 1
Istanbul 1
Itaperuna 1
Lages 1
Lorena 1
Los Angeles 1
Madison 1
Miami 1
Milan 1
Monmouth Junction 1
Monsenhor Paulo 1
Montreal 1
Moscow 1
New Orleans 1
Newark 1
Newport News 1
Niterói 1
Nuremberg 1
Pinheiro 1
Poplar 1
Praia Grande 1
Princeton 1
Rabat 1
Redwood City 1
Rio Branco 1
Rio de Janeiro 1
Riyadh 1
Roxbury 1
Sacramento 1
San Francisco 1
San Gil 1
San Juan Bautista 1
Santa Clara 1
Santa Maria 1
Seoul 1
Stockholm 1
Thái Nguyên 1
Viedma 1
Totale 161
Nome #
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial 124
Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): A study protocol 83
Totale 207
Categoria #
all - tutte 1.187
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.187


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202211 0 0 0 0 1 2 0 0 0 2 4 2
2022/202331 2 5 1 1 1 5 6 3 5 0 0 2
2023/20246 3 0 0 0 0 2 0 0 0 0 0 1
2024/202536 1 0 8 0 0 5 1 1 1 2 7 10
2025/202689 13 5 6 14 6 1 5 8 12 8 7 4
2026/20276 2 3 1 0 0 0 0 0 0 0 0 0
Totale 207